Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

Running, not enrolling · Phase 2/Phase 3

Conditions studied: Huntington Disease

In brief

Examine the effects of deutetrabenazine on functional speech and gait impairment

Key facts

Study ID

NCT04713982

Run by

Vanderbilt University Medical Center

People needed

30

Starts

2021-11-19

Expected to finish

2027-10-01

Last updated by the study team

2026-08-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of HD with documented CAG repeat ≥ 37
• UHDRS total maximal chorea score of ≥ 8
• Able to walk at least 10 meters
• Medically stable outpatient, based on the investigator's judgment
• Willing and able to give written informed consent prior to performing any study procedures
• Have completed at least 10th grade
• Montreal Cognitive Assessment score ≥ 22 on screening
• Female subjects of childbearing potential agree to use an acceptable method of contraception from screening through study completion

You may not qualify if…

• Severe depression or suicidal ideation
• History of suicidal behavior
• Unstable or serious medical or psychiatric illness
• Renal or hepatic impairment
• Severe speech impairment or anarthria
• Inability to swallow study medication
• Women who are pregnant or breast feeding
• History of alcohol or substance abuse within the last 12 months
• Current use of VMAT2 inhibitor (tetrabenazine, deutetrabenazine, valbenazine)
• Concurrent participation in any other investigational drug trials
• EKG QTcF> 500 mse

Where it is running

• Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.